En Es
Categories

Industry News

Global Lateral Flow Assays Market to Reach USD 13.85 Billion by 2027 Due to Benefits of Rapid Tests and Growing Demand for POC Testing

By Labmedica International staff writers
20 May 2021

IllustrationThe global lateral flow assays market is expected to grow at a CAGR of 8.8% from 2020 to 2027 to reach USD 13.85 billion by 2027, driven mainly by the benefits of LFA-based rapid tests over laboratory testing and growing demand for point-of-care testing.

These are the latest findings of Meticulous Research (Redding, CA, USA), a market intelligence provider.

Lateral flow assays are devices used to confirm the presence or absence of a target analyte without the need for lab equipment. These devices are widely used in hospitals and clinical laboratories for the qualitative and quantitative detection of specific antigens and antibodies. It is a simple and low-cost technology used in qualitative and quantitative detection of pathogens or biomarkers in humans or animals, or contaminants or toxic elements in water supplies, foodstuffs, or animal feeds.

The growth of the overall lateral flow assays market is mainly attributed to the benefits of LFA-based rapid tests over laboratory testing, increasing usage of home-based lateral flow assay kits, growing demand for point-of-care testing, increasing prevalence of chronic & infectious diseases, and growing acceptance of smart devices. In addition, evolving applications of lateral flow assays and rising demand for lateral flow assays in the food & beverage industry offer significant growth opportunities for players operating in the lateral flow assays market. On the other hand, the reluctance towards changing existing diagnostic practices and the development of multiplexing assays are some of the factors challenging the growth of this market to a certain extent. Also, variance in lateral flow assay test results and stringent regulations are expected to hinder the growth of this market.

Based on product, the kits & reagents segment accounted for the largest share of the overall lateral flow assays market in 2020, led by the higher adoption rate of kits & reagents, increasing use of home-based lateral flow assay devices, and growing demand for point-of-care testing. On the basis of technique, the sandwich assays segment accounted for the largest share of the overall lateral flow assays market in 2020, due to the wide application of sandwich assays in various medical testing settings and their advantages, such as higher sensitivity and specificity for larger analytes.

Based on application, the clinical testing segment accounted for the largest share of the overall lateral flow assays market in 2020, on the back of increasing healthcare expenditure, rising initiatives towards health awareness, growing awareness about clinical testing, and increasing spread of various chronic and infectious diseases. Based on end user, diagnostic laboratories accounted for the largest share of the overall lateral flow assays market in 2020, on account of increasing adoption of lateral flow assays due to their benefits over conventional laboratory tests, increasing use of PoC tests, growing hospital admissions, and rapid growth in demand for lateral flow tests during COVID-19. Geographically, North America accounted for the largest share of the global lateral flow assays market in 2020, followed by Europe and Asia-Pacific. The increasing prevalence of chronic and infectious diseases, rising geriatric population, growing demand for point-of-care testing facilities, and presence of key players in the region are driving the growth of the North American lateral flow assays market.

Related Links:
Meticulous Research



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

15 Jun 2021
Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device
Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition to the Sofia and Sofia 2 line of Fluorescent Immunoassay Analyzers (FIA).
Read More
15 Jun 2021
Global PET-CT Scanner Device Market to Reach USD 3.34 Billion by 2028
The global PET-CT scanner device market size is expected to register a CAGR of 6.6% from 2021 to 2028 to reach USD 3.34 billion by 2028, driven primarily by the increasing need to overcome the shortfalls of CT and PET in oncology imaging.
Read More
11 Jun 2021
Global Clinical Chemistry Analyzers Market to Reach USD 15.97 Billion by 2028
The global clinical chemistry analyzers market is projected to grow at a CAGR of 4.25% from USD 11.45 billion in 2020 to USD 15.97 billion by 2028, driven by growth in technology, rising global population, technological improvements in point of care testing devices, and development of laboratory automation.
Read More
09 Jun 2021
Global COVID-19 Saliva Screening Test Market to Reach USD 3,406.2 Billion by 2023
The global COVID-19 saliva screening test potential market size is expected to expand at a CAGR of 4.8% from USD 2955.9 billion in 2021 to USD 3,406.2 billion by 2023, driven by a rise in the demand for rapid, efficient, saliva-based screening tests.
Read More
18 May 2021
PerkinElmer to Acquire UK In-Vitro Diagnostics Company Immunodiagnostic Systems
PerkinElmer, Inc. (Waltham, MA; USA) and Immunodiagnostic Systems Holdings PLC (IDS; Boldon, Tyne and Wear, UK) have reached an agreement whereby PerkinElmer will acquire IDS for approximately USD 155 million.
Read More
14 May 2021
Siemens Launches its Fastest, Single-Source CT Scanner, Somatom X.ceed
Siemens Healthineers (Erlangen, Germany) has launched Somatom X.ceed, a new high-resolution, high-speed CT (computed tomography) scanner engineered specifically for the most challenging clinical areas where time and precision are of essence.
Read More
14 May 2021
Carestream Unveils Groundbreaking AI-Based Technology that Advances X-Ray Image Quality
Carestream Health (Rochester, N.Y., USA) has released Smart Noise Cancellation (SNC), a groundbreaking artificial intelligence (AI)-based technology that greatly improves image quality - producing images that are significantly clearer than with standard processing.
Read More
12 May 2021
Artificial Intelligence (AI) Program Accurately Predicts Lung Cancer Risk from CT Images
An artificial intelligence (AI) program accurately predicts the risk that lung nodules detected on screening CT will become cancerous, according to a study published in the journal Radiology.
Read More
05 May 2021
Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories
Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions